7-minute VR experience significantly increases HIV medication adherence

After participating in a seven-minute educational, interactive experience through a virtual reality headset, patients showed improvements in adherence to a regimen of highly active antiretroviral therapy (HAART) medications, according to a new study in the Interactive Journal of Medical Research.

Advertisement

More than 100 patients with HIV viewed the VR experience, which illustrated the mechanisms of immune cells, HIV and antiretroviral medications, showing the importance of HAART adherence. Each patient self-reported how often they take their medication two weeks before and after viewing the video, and also had blood tests both before and several months after the experience.

After the VR experience, patients were significantly more likely to report having complied with their treatment regimen, with the results of their follow-up viral load and CD4 blood tests reflecting that increase. As a result, according to the study’s authors, widespread use of this quick and low-cost VR experience could have a hugely beneficial impact on the approximately 40 percent of people with HIV whose medication compliance falls below 90 percent, the threshold for high treatment efficacy.

More articles about health IT:
MIT 3D-printing technique could produce highly customized ankle braces, hernia mesh
Study: Google beats Amazon, Apple voice assistants in comprehension of medication info requests
Philips updates AI-enabled cardiac ultrasound platform to make it faster, easier to use

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.